Ex-Pfizer SVP takes the helm at BioClinica

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.

Ex-Pfizer SVP takes the helm at BioClinica

BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer ($PFE), where he worked as senior vice president and worldwide head of development operations. The move sees Hubbard step back into the vendor and service provider sector, a field with which he is familiar. Prior to joining Pfizer, Hubbard headed up clinical research services at Icon ($ICLR). Release

John Hubbard became the new CEO.

Julie Gerberding is stepping down from her post as vaccines president.


> Julie Gerberding, president of Merck's ($MRK) vaccines unit, will be moving on come mid-December for a new role as executive vice president for strategic communications, global public policy and population health, the company announced Wednesday. Release


Innocoll ($INNL) appointed Tony Zook as the company's CEO. Release

John Tchelingerian joined Promethera Biosciences as the new chairman of the board. Release

Batu Biologics brought on Gerry Berg as its chief financial officer. Release

XTL Biopharmaceuticals ($XTLB) appointed Jonathan Schapiro and Dobroslav Melamed to its board of directors. Release

Amarantus BioSciences appointed Amgen ($AMGN) co-founder Joseph Rubinfeld to its board of directors. Release

Leidos hired Steven Russell as its senior vice president for sales and strategic accounts. Release

ATS Labs, now Accuratus Lab Services, brought on Eric Hess as its CEO. Release

Dr. Yan Sun joined Beyondspring Pharmaceuticals as the principal investigator for its Phase III lung cancer trial of plinabulin. Release

Arcturus Therapeutics appointed Dr. Michael Hodges to its scientific advisory board. Release

INC Research ($INCR) appointed Richard Kender to its board of directors. Release

> Cytovance Biologics appoints Don Wuchterl as chief operating officer. Release

> Soligenix appointed Oreola Donini as senior vice president and chief scientific officer. Release

CBSET appointed Dr. Haim Danenberg as chief scientific adviser. Release

OvaScience ($OVAS) promoted Arthur Tzianabos to president, Theresa McNeely to EVP, and appointed David Harding as chief commercial officer. Release

Dan Glickman joined Pathway Genomics' Strategic Advisory Board. Release

> The Illinois Biotechnology Industry Organization elected Daniel Brennan, Jamie Oldani, Susanne Resatz and Geeta Vemuri to its board of directors. Release

Elise Brownell was appointed as Amarantus Biosciences' SVP of operations and project management. Release

> Dr. Fred T. Fiedorek was named chief medical officer by Rhythm. Release


Aquinox Pharmaceuticals appointed David Mitchell as its vice president of global regulatory affairs and quality assurance. Release

> Don deBethizy joins Berlin-based Noxxon Pharma's supervisory board. Release

> Thomas G. Auchincloss Jr. will join Concert Pharmaceuticals' ($CNCE) board of directors and will serve as the independent chair of the board's audit committee. Release

> Agios Pharmaceuticals ($AGIO) appoints Kaye Foster-Cheek to its board of directors. Release

> Christine Silverstein joins Relmada Therapeutics as director of investor relations. Release

> Parnell Pharmaceuticals Holdings shakes up its management team, appointing Edward Robb as chief scientific officer, Andy Ferrigno as vice president of global sales and Thomas Duley as a member of the board of directors and member of the audit committee. Release


Peter Kant joined SRI International as the executive director of its Center for Science, Technology and Economic Development. Release

Biotech Research

The Glenn Foundation for Medical Research brought on Kevin Lee as its senior adviser. Release

Medical Devices

HeartFlow appointed former Johnson & Johnson ($JNJ) CEO William Weldon to its board of directors. Release


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.